Physician profile
Robert Bass
NPI 1457328726
$5,907.84
in general payments reported to CMS, 2019-2025
21 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,165 · 2020: $215 · 2021: $485 · 2022: $678 · 2023: $448 · 2024: $789 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $1,807.82 | 2019 | |
| Abbvie INC. | $1,187.38 | 2019-2025 | Linzess, Viberzi |
| Janssen Biotech, INC. | $1,010.23 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $532.41 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $440.18 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $314.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $90.77 | 2019-2025 | |
| Celgene Corporation | $79.42 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $67.53 | 2023-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $62.59 | 2020-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $52.64 | 2023-2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $49.24 | 2019-2024 | Ocaliva |
| Genzyme Corporation | $40.83 | 2024-2025 | |
| Lilly USA, LLC | $34.23 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $34.12 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31.91 | 2022-2024 | Dupixent |
| Masimo Corporation | $24.73 | 2021 | |
| Ardelyx, INC. | $17.55 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $16.76 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $12.55 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.